The use of mechanical support devices in the pediatric population is an area of active investigation. The authors evaluated all pediatric patients at a single institution who presented in cardiogenic shock and were treated with an Impella device. A total of six patients were observed, who received Impella 2.5, Impella CP, and Impella 5.5, with a median duration of support of seven days (range: 4-45 days). Of these, two patients were bridged to recovery, three to left ventricular assist device (LVAD), and one to heart transplant. Given the absence of mortality or neurological complications, the authors suggest that use the of the Impella device is safe and feasible in this patient population.